Cargando…

Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease

Alzheimer’s disease is a neurodegenerative disease that accounts for most of the 50-million dementia cases worldwide in 2018. A large amount of evidence supports the amyloid cascade hypothesis, which states that amyloid-beta accumulation triggers tau hyperphosphorylation and aggregation in form of n...

Descripción completa

Detalles Bibliográficos
Autores principales: Roda, Alejandro R., Serra-Mir, Gabriel, Montoliu-Gaya, Laia, Tiessler, Lidia, Villegas, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820696/
https://www.ncbi.nlm.nih.gov/pubmed/35017413
http://dx.doi.org/10.4103/1673-5374.332127
_version_ 1784646257013161984
author Roda, Alejandro R.
Serra-Mir, Gabriel
Montoliu-Gaya, Laia
Tiessler, Lidia
Villegas, Sandra
author_facet Roda, Alejandro R.
Serra-Mir, Gabriel
Montoliu-Gaya, Laia
Tiessler, Lidia
Villegas, Sandra
author_sort Roda, Alejandro R.
collection PubMed
description Alzheimer’s disease is a neurodegenerative disease that accounts for most of the 50-million dementia cases worldwide in 2018. A large amount of evidence supports the amyloid cascade hypothesis, which states that amyloid-beta accumulation triggers tau hyperphosphorylation and aggregation in form of neurofibrillary tangles, and these aggregates lead to inflammation, synaptic impairment, neuronal loss, and thus to cognitive decline and behavioral abnormalities. The poor correlation found between cognitive decline and amyloid plaques, have led the scientific community to question whether amyloid-beta accumulation is actually triggering neurodegeneration in Alzheimer’s disease. The occurrence of tau neurofibrillary tangles better correlates to neuronal loss and clinical symptoms and, although amyloid-beta may initiate the cascade of events, tau impairment is likely the effector molecule of neurodegeneration. Recently, it has been shown that amyloid-beta and tau cooperatively work to impair transcription of genes involved in synaptic function and, more importantly, that downregulation of tau partially reverses transcriptional perturbations. Despite mounting evidence points to an interplay between amyloid-beta and tau, some factors could independently affect both pathologies. Thus, the dual pathway hypothesis, which states that there are common upstream triggers causing both amyloid-beta and tau abnormalities has been proposed. Among others, the immune system seems to be strongly involved in amyloid-beta and tau pathologies. Other factors, as the apolipoprotein E ε4 isoform has been suggested to act as a link between amyloid-beta and tau hyperphosphorylation. Interestingly, amyloid-beta-immunotherapy reduces not only amyloid-beta but also tau levels in animal models and in clinical trials. Likewise, it has been shown that tau-immunotherapy also reduces amyloid-beta levels. Thus, even though amyloid-beta immunotherapy is more advanced than tau-immunotherapy, combined amyloid-beta and tau-directed therapies at early stages of the disease have recently been proposed as a strategy to stop the progression of Alzheimer’s disease.
format Online
Article
Text
id pubmed-8820696
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-88206962022-02-24 Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease Roda, Alejandro R. Serra-Mir, Gabriel Montoliu-Gaya, Laia Tiessler, Lidia Villegas, Sandra Neural Regen Res Review Alzheimer’s disease is a neurodegenerative disease that accounts for most of the 50-million dementia cases worldwide in 2018. A large amount of evidence supports the amyloid cascade hypothesis, which states that amyloid-beta accumulation triggers tau hyperphosphorylation and aggregation in form of neurofibrillary tangles, and these aggregates lead to inflammation, synaptic impairment, neuronal loss, and thus to cognitive decline and behavioral abnormalities. The poor correlation found between cognitive decline and amyloid plaques, have led the scientific community to question whether amyloid-beta accumulation is actually triggering neurodegeneration in Alzheimer’s disease. The occurrence of tau neurofibrillary tangles better correlates to neuronal loss and clinical symptoms and, although amyloid-beta may initiate the cascade of events, tau impairment is likely the effector molecule of neurodegeneration. Recently, it has been shown that amyloid-beta and tau cooperatively work to impair transcription of genes involved in synaptic function and, more importantly, that downregulation of tau partially reverses transcriptional perturbations. Despite mounting evidence points to an interplay between amyloid-beta and tau, some factors could independently affect both pathologies. Thus, the dual pathway hypothesis, which states that there are common upstream triggers causing both amyloid-beta and tau abnormalities has been proposed. Among others, the immune system seems to be strongly involved in amyloid-beta and tau pathologies. Other factors, as the apolipoprotein E ε4 isoform has been suggested to act as a link between amyloid-beta and tau hyperphosphorylation. Interestingly, amyloid-beta-immunotherapy reduces not only amyloid-beta but also tau levels in animal models and in clinical trials. Likewise, it has been shown that tau-immunotherapy also reduces amyloid-beta levels. Thus, even though amyloid-beta immunotherapy is more advanced than tau-immunotherapy, combined amyloid-beta and tau-directed therapies at early stages of the disease have recently been proposed as a strategy to stop the progression of Alzheimer’s disease. Wolters Kluwer - Medknow 2022-01-07 /pmc/articles/PMC8820696/ /pubmed/35017413 http://dx.doi.org/10.4103/1673-5374.332127 Text en Copyright: © Neural Regeneration Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review
Roda, Alejandro R.
Serra-Mir, Gabriel
Montoliu-Gaya, Laia
Tiessler, Lidia
Villegas, Sandra
Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
title Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
title_full Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
title_fullStr Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
title_full_unstemmed Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
title_short Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
title_sort amyloid-beta peptide and tau protein crosstalk in alzheimer’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820696/
https://www.ncbi.nlm.nih.gov/pubmed/35017413
http://dx.doi.org/10.4103/1673-5374.332127
work_keys_str_mv AT rodaalejandror amyloidbetapeptideandtauproteincrosstalkinalzheimersdisease
AT serramirgabriel amyloidbetapeptideandtauproteincrosstalkinalzheimersdisease
AT montoliugayalaia amyloidbetapeptideandtauproteincrosstalkinalzheimersdisease
AT tiesslerlidia amyloidbetapeptideandtauproteincrosstalkinalzheimersdisease
AT villegassandra amyloidbetapeptideandtauproteincrosstalkinalzheimersdisease